Meta Biomed Co., Ltd. announces an Equity Buyback for KRW 500 million worth of its shares.
June 28, 2022 at 10:09 pm EDT
Share
Meta Biomed Co., Ltd. (KOSDAQ:A059210) announces a share repurchase program. Under the program, the company will repurchase up to KRW 500 million worth of its shares according to the contract with KB Securities. The purpose of the program is stock price stability and shareholder value enhancement.
The program will be valid till June 28, 2024. As of June 28, 2022, the company had 991,243 and 0 treasury stock holdings within the scope of allotment Acquisition Co., Ltd. and Other Acquisition Co., Ltd., respectively.
Meta Biomed Co., Ltd. is a Korea-based company engaged in the manufacture of medical materials and equipment for biotechnology and dental areas. The Company mainly operates its business through three divisions: suture material division, dental division and bone material division. Its suture material division provides suture materials, such as polyglycolic acid (PGA) synthetic absorbable braids, polyglycolic acid-co-lactic acid (PGLA) absorbable braids, polydioxanone (PDO) synthetic absorbable monofilaments, polyglycolide-co-epsilon-caprolactone (PGCL) synthetic absorbable monofilaments and others. Its dental division provides dental materials and equipment, such as gutta percha cordless obturation systems, electronic apex locators, taper points, root canal sealers, root canal filling materials and others. Its bone materials division provides bone graft substitutes. It also distributes dental-related products.
META BIOMED CO., LTD. 
